Diamyd Medical Gestion

Gestion contrôle des critères 3/4

Le PDG Diamyd Medical est Ulf Hannelius, nommé en Apr2016, a un mandat de 8.58 ans. La rémunération annuelle totale est SEK 3.01M, composée du salaire de 70.9% et des bonus 29.1%, y compris les actions et options de la société. détient directement 0.27% des actions de la société, d'une valeur de SEK 3.66M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.8 ans et 20.8 ans.

Informations clés

Ulf Hannelius

Directeur général

SEK 3.0m

Rémunération totale

Pourcentage du salaire du PDG	70.9%
Durée du mandat du directeur général	8.6yrs
Propriété du PDG	0.3%
Durée moyenne d'occupation des postes de direction	4.8yrs
Durée moyenne du mandat des membres du conseil d'administration	20.8yrs

Mises à jour récentes de la gestion

Recent updates

We're Keeping An Eye On Diamyd Medical's (STO:DMYD B) Cash Burn Rate

Feb 02

We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully

Sep 22

What You Need To Know About Diamyd Medical AB (publ)'s (STO:DMYD B) Investor Composition

Jan 22

Here's Why Diamyd Medical's (STO:DMYD B) Statutory Earnings Are Arguably Too Conservative

Nov 30

Analyse de la rémunération des PDG

Comment la rémunération de Ulf Hannelius a-t-elle évolué par rapport aux bénéfices de Diamyd Medical?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Aug 31 2024	n/a	n/a	-SEK 152m
May 31 2024	n/a	n/a	-SEK 140m
Feb 29 2024	n/a	n/a	-SEK 120m
Nov 30 2023	n/a	n/a	-SEK 116m
Aug 31 2023	SEK 3m	SEK 2m	-SEK 116m
May 31 2023	n/a	n/a	-SEK 119m
Feb 28 2023	n/a	n/a	-SEK 115m
Nov 30 2022	n/a	n/a	-SEK 99m
Aug 31 2022	SEK 3m	SEK 2m	-SEK 104m
May 31 2022	n/a	n/a	-SEK 91m
Feb 28 2022	n/a	n/a	-SEK 106m
Nov 30 2021	n/a	n/a	-SEK 83m
Aug 31 2021	SEK 3m	SEK 2m	SEK 60m
May 31 2021	n/a	n/a	SEK 74m
Feb 28 2021	n/a	n/a	SEK 99m
Nov 30 2020	n/a	n/a	SEK 121m
Aug 31 2020	SEK 3m	SEK 2m	SEK 10m
May 31 2020	n/a	n/a	SEK 13m
Feb 29 2020	n/a	n/a	SEK 13m
Nov 30 2019	n/a	n/a	-SEK 35m
Aug 31 2019	SEK 2m	SEK 1m	-SEK 37m
May 31 2019	n/a	n/a	-SEK 38m
Feb 28 2019	n/a	n/a	-SEK 43m
Nov 30 2018	n/a	n/a	-SEK 42m
Aug 31 2018	SEK 2m	SEK 1m	-SEK 44m

Rémunération vs marché: La rémunération totale de Ulf ($USD 273.40K ) est dans la moyenne des entreprises de taille similaire sur le marché Swedish ($USD 236.30K ).

Rémunération et revenus: La rémunération de Ulf a augmenté alors que l'entreprise n'est pas rentable.

PDG

Ulf Hannelius (49 yo)

8.6yrs

Titularisation

SEK 3,006,000

Compensation

Mr. Ulf Hannelius, PhD, MBA, has been the Chief Executive Officer of Diamyd Medical AB (publ) since April 11, 2016 and serves as its President. Mr. Hannelius served as an Interim Chief Executive Officer at...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Ulf Hannelius	CEO & President	8.6yrs	SEK 3.01m	0.27% SEK 3.6m
Anna Styrud	Chief Financial Officer	no data	pas de données	0.14% SEK 1.8m
Martina Widman	Chief Operating Officer	2.4yrs	pas de données	0.012% SEK 157.5k
Anton Lindqvist	Chief Scientific Officer	7.2yrs	pas de données	pas de données
Maja Johansson	Chief Operating Officer of Manufacturing Site	1.8yrs	pas de données	0.0024% SEK 31.5k

4.8yrs

Durée moyenne de l'emploi

49yo

Âge moyen

Gestion expérimentée: L'équipe de direction de DMYD B est considérée comme expérimentée (ancienneté moyenne 4.8 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Ake Lernmark	Member of the Scientific Advisory Board	28.8yrs	pas de données	pas de données
David Leslie	Member of the Scientific Advisory Board	25.8yrs	pas de données	pas de données
Daniel Kaufman	Member of the Scientific Advisory Board	28.8yrs	pas de données	pas de données
Anders Essen-Möller	Independent Chairman	28.8yrs	SEK 1.06m	3.13% SEK 41.1m
Mark Atkinson	Chairman of Scientific Advisory Board & Independent Director	27.8yrs	SEK 175.00k	0.016% SEK 211.0k
Karin Hehenberger	Independent Director	3.6yrs	SEK 125.00k	0.0096% SEK 126.0k
Erik Nerpin	Independent Vice Chairman	12.8yrs	SEK 230.00k	0.056% SEK 740.0k
Torbjörn Bäckström	Independent Director	7.8yrs	SEK 138.00k	0.00096% SEK 12.6k
Maria-Teresa Essen-Möller	Independent Director	15.8yrs	SEK 164.00k	1.31% SEK 17.2m
Karin Rosen	Independent Director	1.7yrs	SEK 28.00k	0.000010% SEK 131.2

20.8yrs

Durée moyenne de l'emploi

65.5yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la DMYD B est chevronné et expérimenté ( 20.8 années d'ancienneté moyenne).

Diamyd Medical Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Diamyd Medical AB (publ), Annual General Meeting, Dec 05, 2024

CEO & President exercised options to buy kr660k worth of stock.

Independent Chairman recently sold kr651k worth of stock

Diamyd Medical AB (Publ) Elects Karin Rosén as A New Member of the Board

Chairman recently bought kr72k worth of stock

Diamyd Medical AB (Publ) Announces Changes of the Board

Recent updates

Diamyd Medical AB (publ) Hits a Recruitment Milestone in DIAGNODE-3 Phase 3 Trial

Diamyd Medical AB (publ), Annual General Meeting, Dec 05, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Diamyd Medical AB (publ) to Report Q1, 2025 Results on Jan 29, 2025

CEO & President exercised options to buy kr660k worth of stock.

Diamyd Medical to Pursue Accelerated Approval Pathway for Type 1 Diabetes Precision Medicine

Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes

New major risk - Share price stability

Third quarter 2024 earnings released

Diamyd Medical AB (publ) to Report Q4, 2024 Results on Nov 14, 2024

Diamyd Medical AB (publ) Updates on the Registrational Phase 3 Trial

Independent Chairman recently sold kr651k worth of stock

Recruitment Milestone Reaches in Diamyd® Phase 3 Trial

Second quarter 2024 earnings released

New minor risk - Share price stability

We're Keeping An Eye On Diamyd Medical's (STO:DMYD B) Cash Burn Rate

First quarter 2024 earnings released

In-Depth Analysis of Diamyd Medical AB (publ)'s Phase II Trial Further Supports Value of Presented Insulin Production

Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea

Diamyd Medical AB (Publ) Elects Karin Rosén as A New Member of the Board

Diamyd Medical AB (publ) to Report Fiscal Year 2023 Results on Nov 30, 2023

Chairman recently bought kr72k worth of stock

Diamyd Medical AB (publ) has completed a Composite Units Offering in the amount of SEK 69.834709 million.

Diamyd Medical AB (Publ) Announces Follow-Up Study Recommends Diamyd to Offer Advantages in Delivering Type 1 Diabetes Onset

Diamyd Medical AB (publ) Announces Preliminary Results from Booster Trial with Diamyd Provide Additional Support for Intralymphatic Injection

Diamyd Medical AB (publ) to Report Q2, 2024 Results on Mar 27, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Diamyd Medical AB (Publ) Announces Changes of the Board

We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully

Diamyd Medical AB (Publ) Announces Registrational Phase III Trial in Type 1 Diabetes with Diamyd Expands to the US

New minor risk - Shareholder dilution

Price target decreased by 27% to kr19.00

Diamyd Medical AB (publ), Annual General Meeting, Nov 30, 2023

Third quarter 2023 earnings released

CEO & President recently bought kr88k worth of stock

Second quarter 2023 earnings released

Diamyd Medical Receives Patent Protection in the US and Japan for Gaba Formulation Remygen

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.52 loss in 1Q 2022)

Diamyd Medical Precision Medicine Patent for Prevention and Treatment of Autoimmune Diabetes to Be Granted in Eurasia

Diamyd Medical AB (Publ) Announces US Partial Clinical Hold on Diamyd® Phase III Trial Lifted by the FDA

Price target increased to kr19.50

Full year 2022 earnings released: kr1.35 loss per share (vs kr0.86 profit in FY 2021)

All Patients in DIAGNODE-B Have Received an Additional (Booster) Injection of Diamyd

Diamyd Medical AB (publ) to Report Q3, 2023 Results on Jun 28, 2023

Third quarter 2022 earnings released

Diamyd Medical AB (publ), Annual General Meeting, Dec 01, 2022

Diamyd Medical AB (publ) Announces First Patient Enrolled in its Phase III Trial DIAGNODE-3

Price target increased to kr19.50

Director recently sold kr1.0m worth of stock

Diamyd Medical AB Announces New Clinical Trial Will Evaluate an Additional Injection (Booster) with Diamyd

Second quarter 2022 earnings: Revenues miss analyst expectations

Clinical Trial in Type 1 Diabetes with Diamyd Medical's Remygen Is Fully Recruited

Diamyd Medical Proceeds with Initiation of Type 1 Diabetes Phase III Trial in Europe

First quarter 2022 earnings: Revenues miss analyst expectations

Diamyd Medical AB Patent for Intralymphatic Injection of GAD in Autoimmune Diabetes to Be Granted in China

Diamyd Medical Announces Australia Grants as the First Region Diamyd Medical A Broadening of A Patent for Intralymphatic Injection of Antigens in Autoimmune Diabetes

Director recently sold kr3.7m worth of stock

Diamyd Medical Pauses Start of Phase III Trial

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS kr0.86 (vs kr0.14 in FY 2020)

CEO & President recently bought kr112k worth of stock

CEO & President recently bought kr112k worth of stock

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS kr0.84 (vs kr0.14 in FY 2020)

Diamyd Medical AB Receives First Regulatory Approval to Start the Phase III Trial DIAGNODE-3 with the Diabetes Vaccine Diamyd®

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Diamyd Medical AB (Publ) Announces 24-Month Follow-Up of Phase IIb Diamyd® Clinical Trial Indicates Continued Similar Progression After 15 Months